The world’s main dementia scientists talk about the controversies surrounding new Alzheimer’s medicine.
Dementia impacts 55 million individuals worldwide, and its commonest type, Alzheimer’s, accounts for about 70 % of all circumstances.
On the Alzheimer’s Affiliation Worldwide Convention, the most important congress supporting dementia science, held in Amsterdam this month, a pharmaceutical firm revealed particulars of its new drug trial: donanemab.
The US firm, Eli Lilly, expects the US Meals and Drug Administration (FDA) to resolve by the tip of 2023 whether or not to approve what it calls a “breakthrough” drug.
However is that this medication the easiest way ahead? Or does it simply present money circulation for the pharmaceutical business?
Main dementia scientists Ed Richard and Craig Ritchie spoke to Al Jazeera.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?